<DOC>
	<DOCNO>NCT01481779</DOCNO>
	<brief_summary>The purpose study : - To compare blood sugar control LY2605541 insulin glargine 78 week treatment . - To compare number night time low blood sugar episode LY2605541 insulin glargine 78 week treatment . - To compare number participant LY2605541 reach blood sugar target without low blood sugar episode night take insulin glargine 78 week treatment . - To compare total number low blood sugar episode LY2605541 insulin glargine 78 week treatment .</brief_summary>
	<brief_title>A Study Participants With Type 1 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Lispro</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Have diabetes least 1 year Have HbA1c value le 12 % accord central laboratory screen Have body mass index ( BMI ) less equal 35.0 kg/m^2 Have treat least 90 day prior screen : insulin detemir , insulin glargine , human insulin isophane suspension ( NPH ) insulin combination premeal insulin , selfmixed premixed insulin regimen basal bolus insulin combination administer least twice daily , continuous subcutaneous insulin infusion therapy This inclusion criterion applies female Are breastfeed Test negative pregnancy screen randomization base serum pregnancy test Intend become pregnant study Have practice reliable method birth control ( example , use oral contraceptive levonorgestrel ; diaphragms contraceptive jelly ; cervical cap contraceptive jelly ; condom contraceptive foam ; intrauterine device ; partner vasectomy ; abstinence ) least 6 week prior screen Agree continue use reliable method birth control study , determine investigator ( 2 week follow last dose study drug ) Capable , willing desirous following : adhere multiple daily injection regimen , inject insulin prefilled pen perform SelfMonitored Blood Glucose ( SMBG ) record keep require protocol , determine investigator . Caregiver may Are use twice daily insulin glargine inadequately control single daily dose glargine prior screen Excessive insulin resistance define received total daily dose insulin great 1.5 U/kg time randomization Receiving oral injectable medication ( metformin treatment polycystic ovarian disease ) intend treatment diabetes mellitus insulins 90 day prior screen Lipidlowering medication : use niacin preparation lipidlowering medication and/or bile acid sequestrants within 90 day prior screen ; , use lipidlowering medication dose stable great equal 90 day prior screen If participant stable dose lipidlowering medication great equal 90 day prior screen , site wait screen participant . If result screen laboratory test require change participant 's current lipidlowering medication initiation lipidlowering medication , acceptable change lipidlowering medication participant participant return great equal 90 day later complete screening procedure Have fast hypertriglyceridemia ( define great 4.5 mmol/L , great 400 mg/dl ) screening , determined central laboratory Have 1 episode severe hypoglycemia ( define require assistance due neurologically disable hypoglycemia determine investigator ) within 6 month prior entry study Have 2 emergency room visit hospitalization due poor glucose control ( hyperglycemia diabetic ketoacidosis ) past 6 month Cardiovascular : cardiac disease functional status New York Heart Association Class III IV ( per NYHA Cardiac Disease Classification ) Renal : Have history renal transplantation currently receive renal dialysis serum creatinine great 2.5 mg/dL Hepatic : obvious clinical sign symptom liver disease ( exclude nonalcoholic fatty liver disease [ NAFLD ] ) , acute chronic hepatitis , non alcoholic steatohepatitis ( NASH ) , elevate liver enzyme measurement indicate : total bilirubin great equal 2 time upper limit normal ( ULN ) define central laboratory , alanine aminotransferase ( ALT ) / ( serum glutamic pyruvic transaminase ( SGPT ) great 2.5 time ULN define central laboratory , aspartate aminotransferase ( AST ) /serum glutamic oxaloacetic transaminase ( SGOT ) great 2.5 time ULN define central laboratory Malignancy : Have active untreated malignancy , remission clinically significant malignancy ( basal cell squamous cell skin cancer ) less 5 year , increase risk develop cancer recurrence cancer opinion investigator Allergy : Have know hypersensitivity allergy study insulins excipients Hematologic : Have blood transfusion severe blood loss within 3 month prior screen know hemoglobinopathy , hemolytic anemia , sickle cell anemia , traits hemoglobin abnormality know interfere HbA1c measurement Glucocorticoid therapy : Receiving chronic ( lasting longer 14 consecutive day ) systemic glucocorticoid therapy ( exclude topical , intraocular , intranasal , inhaled preparation ) receive therapy within 8 week immediately screen exception replacement therapy adrenal insufficiency Diagnosed clinically significant diabetic autonomic neuropathy , opinion investigator Have condition ( include know drug alcohol abuse psychiatric disorder include eat disorder ) preclude participant follow completing protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>